Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Something to look forward too

<< Previous

Bullboard Posts

Next >>

Comment by Viking2233on Oct 06, 2023 1:26pm

143 Views

Post# 35673522

RE:RE:Something to look forward too

Health Canada and FDA have seen data already, CEO already stated there will be no surprised. Yes the 3rd party review is 800 days old and long overdue but unfortunately is out of companies control when it will be completed and released.

TechTitan wrote: You are excited for the next round of data but....... the first round of data has not been released to the public which has been 792 days since the 3rd party review... got it... and you still state the confusion why there are short sellers and no buyers.........

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec